VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay

November 6, 2012 9:25 AM EST
VIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.

The following are a few key pieces from VIVUS conference call:
  • 3,504 patients are on Qsymia to date;
  • Average price for 1-month supply is $160, with 20 percent reimbursement coverage since launch; and
  • About 30 percent of Qsymia prescriptions are abandoned due to cash outlay.

VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Conference Calls

Related Entities


Add Your Comment